"The U.S. Food and Drug Administration today allowed marketing of the first medical device based on brain function to help assess attention-deficit/hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old. When used as part of "...
hypertension may develop early and may be followed by hypotension, bradycardia, respiratory depression, hypothermia, drowsiness, decreased or absent reflexes, weakness, irritability and miosis. The frequency of CNS depression may be higher in children than adults. Large overdoses may result in reversible cardiac conduction defects or dysrhythmias, apnea, coma and seizures. Signs and symptoms of overdose generally occur within 30 minutes to two hours after exposure.
Consult with a Certified Poison Control Center for up-to-date guidance and advice.
KAPVAY should not be used in patients with known hypersensitivity to clonidine.
Last reviewed on RxList: 2/22/2013
This monograph has been modified to include the generic and brand name in many instances.
Additional Kapvay Information
Report Problems to the Food and Drug Administration
Find out what women really need.